Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy

Cancer Immunology Research

Volumn 2, Issue 6, 2014, Pages 538-546

  Tjin, Esther P M ^a   Krebbers, Gabrielle ^a   Meijlink, Kimberley J ^a   Van De Kasteele, Willeke ^b   Rosenberg, Efraim H ^b   Sanders, Joyce ^b   Nederlof, Petra M ^b   Van De Wiel, Bart A ^b   Haanen, John B A G ^b,c   Melief, Cornelis J M ^d   Vyth Dreese, Florry A ^b   Luiten, Rosalie M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ISA Pharmaceuticals   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; MELANOMA; METABOLISM; MIDDLE AGED; MUTATION; PROCEDURES; SKIN NEOPLASMS; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ESCAPE;

ADULT; AGED; BIOMARKERS, TUMOR; CANCER VACCINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR ESCAPE;

EID: 84990012114     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-13-0097     Document Type: Article

References (37)

1. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006; 119:317-27.
2. Jurado JO, Alvarez IB, Pasquinelli V, Martinez GJ, Quiroga MF, Abbate E, et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 2008; 181:116-25.
3. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537-44.
4. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Leuscher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207:2175-86.
5. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704.
6. Elias EG, Hasselkamp JH, Sharma BK. Cytokines and growth factors expressed by human cutaneous melanoma. Cancers 2013; 2:794-808.
7. Califice S, Castronovo V, Van Den Brule F. Galectin-3 and cancer (Review). Int J Oncol 2004; 25:983-92.
8. Bolander A, Agnarsdottir M, Stromberg S, Ponten F, Hesselius P, Uhlen M, et al. The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas. Cancer Genomics Proteomics 2008; 5:293-300.
9. Kovacs-Solyom F, Blasko A, Fajka-Boja R, Katona RL, Vegh L, Novak J, et al. Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol Lett 2010; 127:108-18.
10. Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 2006; 168: 1666-75.
11. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995; 378:736-9.
12. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5:241-51.
13. Demotte N, Stroobant V, Courtoy PJ, Van der Smissen P, Colau D, Leuscher IF, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008; 28:414-24.
14. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJ Jr, Wunderlich JR, Merino MJ, et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008; 112: 4953-60.
15. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are over-represented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173:1444-53.
16. Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, Banchereau J, et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2007; 104: 20884-9.
17. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74.
18. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222:162-79.
19. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumorinduced tolerance. J Clin Invest 2007; 117:1147-54.
20. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12:547-54.
21. Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, et al. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 1999; 84:160-8.
22. Tjin EP, Konijnenberg D, Krebbers G, Mallo H, Drijfhout JW, Franken KL, et al. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res 2011; 17:5736-47.
23. Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005; 23:8978-91.
24. Gadiot J, Hooijkaas AI, Kaiser AD, van TH, van BH, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011; 117:2192-201.
25. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS ONE 2011; 6:e25806.
26. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011; 17:229-35.
27. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003; 9:3362-8.
28. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29:1239-46.
29. Nagore E, Requena C, Traves V, Guillen C, Hayward NK, Whiteman DC, et al. Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol 2014; 70:858-62.
30. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16:487-94.
31. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999; 154:745-54.
32. Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005; 65:3937-41.
33. van Houdt IS, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG, et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 2008; 123:609-15.
34. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-10.
35. Ladanyi A, Somlai B, Gilde K, Fejos Z, Gaudi I, Timar J. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004; 10:521-30.
36. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumorinfiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007; 25:869-75.
37. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumorinfiltrating immune cells are associated with clinical outcome in met astatic melanoma. Cancer Res 2012; 72:1070-80.